Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the ...

December 23, 2024

Puma Biotechnology announced NCCN updated cervical cancer guidelines to include neratinib monotherapy for HER2-mutated tumors, based on Phase II SUMMIT trial results.

Related Clinical Trials

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Highlighted Terms

Cervical Cancer advanced cervical cancer capecitabine HER2-positive breast cancer neratinib breast cancer endocrine therapy NERLYNX®Puma Biotechnology alisertib National Comprehensive Cancer Network recurrent/metastatic cervical cancer small cell lung cancer NCT01953926 HER2-mutated tumors

Related News

uk.finance.yahoo.com

Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the ...

Puma Biotechnology announced NCCN updated cervical cancer guidelines to include neratinib monotherapy for HER2-mutated tumors, based on Phase II SUMMIT trial results.